Multimodal Monitoring: PbtO2, Microdialysis & Transcranial Doppler

ABPN Neurocritical Care Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Neurologic Examination & Coma Assessment in the ICU

Current Examination, Blueprint & Preparation Neurologic Examination in Critically Ill Patients Coma Evaluation & Consciousness Alterations Delirium & Toxic-Metabolic Encephalopathy in the ICU

2 Chapter 2: Cerebral Physiology & Intracranial Dynamics

Cerebral Blood Flow, Metabolism & Autoregulation Intracranial Pressure & Compliance Cerebral Edema & Herniation Syndromes

3 Chapter 3: Intracranial Hypertension & Cerebral Perfusion Management

Tiered ICP Management Protocols Hyperosmolar Therapy & Fluid Management Advanced & Refractory ICP Interventions

4 Chapter 4: Airway, Mechanical Ventilation & Pulmonary ICU Management

Emergency Airway Management & Neuro-Intubation Mechanical Ventilation Strategies in Acute Brain Injury Tracheostomy & Ventilator Weaning in Neurocritical Care Pulmonary Complications in the Neuro-ICU Obstructive Lung Disease, Pulmonary Hypertension & Bronchoscopy

5 Chapter 5: Hemodynamics, Shock & Cardiovascular Management

Hemodynamic Monitoring & Blood Pressure Targets Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives Cardiac Complications of Brain Injury

6 Chapter 6: Neuropharmacology, Analgesia & Sedation

ICU Sedation & Analgesia Neuromuscular Blockade & Monitoring Propofol Infusion Syndrome & Drug Toxicities Antiseizure Drug Pharmacology in the ICU

7 Bleeding, Thrombosis & Hematologic Emergencies

Warfarin & Heparin Reversal Direct Oral Anticoagulant (DOAC) Reversal Antiplatelet Management & Platelet Dysfunction Venous Thromboembolism Prophylaxis & Management Transfusion, Coagulopathy, TMA & Cellular-Therapy Neurotoxicity

8 Chapter 8: Systemic ICU Care, Fluids, Electrolytes & Endocrine

Hyponatremia & Osmoregulation: SIADH vs Cerebral Salt Wasting Diabetes Insipidus, Hypernatremia & Endocrine Crises Critical Care Prophylaxis, Nutrition & Infection Prevention

9 Systemic Trauma & Environmental Injury

Polytrauma, Chest Injury & Abdominal Hemorrhage Burns, Electrical Injury & Hanging

10 Cardiac Emergencies & Mechanical Support

IABP, Ventricular Devices & ECMO Acute Coronary, Valvular, Rhythm & Aortic Emergencies

11 Kidney Injury, Acid–Base & Renal Replacement

Acute Kidney Injury & Renal Drug Clearance Acid–Base Disorders, Electrolytes & Renal Replacement

12 Systemic Infection & Endocrine Emergencies

Sepsis, Endocarditis & Antimicrobial Principles Thyroid, Adrenal & Dysglycemic Emergencies

13 Gastrointestinal & Hepatic Emergencies

Acute Abdomen, GI Bleeding & Abdominal Compartment Syndrome Acute Liver Failure, Cirrhosis & Hepatic Drug Effects

14 Chapter 9: Neuroimaging in the Neuro-ICU

Non-Contrast CT & CT Angiography CT Perfusion & Advanced Perfusion Imaging Magnetic Resonance Imaging in Critical Illness

15 Chapter 10: Electrophysiology & Neuromonitoring

Continuous EEG & ACNS Standardized Critical Care Terminology Invasive Neuromonitoring: ICP & External Ventricular Drains Multimodal Monitoring: PbtO2, Microdialysis & Transcranial Doppler

16 Angiography, Electrodiagnosis & CSF Analysis

Conventional Angiography & Cranial–Spinal Shunts EMG, Nerve Conduction & Acute Muscle Disease CSF Analysis: Infection, Inflammation & Hemorrhage

17 Chapter 11: Bedside Procedures, Ultrasound & Death by Neurologic Criteria

Critical Care Procedural Skills Critical Care Ultrasound & Echocardiography Determination of Death by Neurologic Criteria

18 Chapter 12: Acute Ischemic Stroke & Reperfusion Therapies

Acute Ischemic Stroke Management & Thrombolysis Endovascular Thrombectomy & Large Vessel Occlusion Malignant Hemispheric & Cerebellar Infarction

19 Chapter 13: Spontaneous Intracerebral Hemorrhage & Intraventricular Hemorrhage

Acute Intraparenchymal Hemorrhage Management Intraventricular Hemorrhage & Hydrocephalus Surgical Evacuation & Minimally Invasive Surgery in ICH

20 Chapter 14: Aneurysmal Subarachnoid Hemorrhage & Delayed Cerebral Ischemia

Aneurysmal Subarachnoid Hemorrhage: Acute Resuscitation & Securing Delayed Cerebral Ischemia & Cerebral Vasospasm Non-Aneurysmal Subarachnoid Hemorrhage & Vascular Malformations

21 Venous, Spinal & Traumatic Vascular Disease

Cerebral Venous Thrombosis & Spinal Cord Infarction Traumatic Dissection, Carotid–Cavernous Fistula & Penetrating Injury

22 Chapter 15: Traumatic Brain & Spinal Cord Injury

Severe Traumatic Brain Injury & Contusions Acute Traumatic Spinal Cord Injury & Neurogenic Shock Spine Trauma, Fractures & Cord Syndromes

23 Chapter 16: Status Epilepticus, Seizures & Neuromuscular Emergencies

Status Epilepticus: Convulsive & Non-Convulsive Refractory & Super-Refractory Status Epilepticus Acute Neuromuscular Respiratory Failure

24 Chapter 17: Post-Cardiac Arrest Care, CNS Infections & Encephalitis

Targeted Temperature Management & Post-Cardiac Arrest Care Post-Cardiac Arrest Neuroprognostication Acute CNS Infections, Encephalitis & Inflammatory Emergencies

25 Neuroinflammation & Neurooncology

Fulminant Demyelination & Autoimmune Encephalitis Brain, Spinal & Leptomeningeal Cancer Emergencies

26 Pregnancy, Transplantation & Pediatric Care

Pregnancy, Postpartum & Post-Transplant Neurologic Care Pediatric Neurocritical Care

27 Chapter 18: Neurosurgical & Perioperative Emergencies

Postoperative Neurosurgical Complications Device Complications: EVDs, Shunts & ICP Monitors Cerebral Hyperperfusion Syndrome & Post-Interventional Emergencies

28 Chapter 19: Ethics, Palliative Care & Organ Donation in the Neuro-ICU

Communication, Surrogate Decision-Making & Conflict Resolution Neuroprognostication Ethics, Withdrawal of Life Support & Palliative Care Organ Donation & Management of the Deceased Donor

Multimodal Monitoring: PbtO2, Microdialysis & Transcranial Doppler

Key Takeaways Explain This Topic AI

PbtO2 is a local measurement; values below common protocol thresholds prompt verification and assessment of oxygen delivery, demand, and perfusion.

BOOST-2 reduced brain hypoxia burden, while OXY-TC did not demonstrate improved six-month outcome; do not invent definitive positive outcome evidence.

Microdialysis LPR, pyruvate, and glucose support interpretation of metabolic disturbance but do not independently prove ischemia or mitochondrial failure.

TCD velocities and ratios support vasospasm surveillance; high velocity alone does not diagnose symptomatic DCI.

Absent Doppler signal alone cannot establish BD/DNC; accepted adult ancillary testing requires technical adequacy and the full guideline framework.

Last updated: October 2026

Multimodal Monitoring: PbtO2, Microdialysis & Transcranial Doppler

Cerebral perfusion pressure (CPP) and intracranial pressure (ICP) provide macroscopic assessments of intracranial hemodynamics. However, adequate CPP does not guarantee sufficient microvascular perfusion, cellular oxygen delivery, or metabolic substrate utilization. Multimodal neuromonitoring integrates invasive parenchymal microprobes with bedside neurovascular ultrasonography to interrogate cellular bioenergetics in real time.

Brain Tissue Oxygenation ( P b t O 2 PbtO_2 P b t O 2 ​ )

Brain tissue oxygen monitoring assesses the balance between cerebral microvascular oxygen delivery and localized metabolic oxygen consumption ( C M R O 2 CMRO_2 CMR O 2 ​ ).

Probe technology: Licox uses a polarographic oxygen sensor, whereas other systems use optical methods. Follow the specific device’s calibration, placement, temperature, and equilibration requirements rather than assuming every commercial probe has the same mechanism.

Physiological Thresholds

Normal Range: 25 – 35 mmHg 25\text{--}35\text{ mmHg} 25 – 35 mmHg .

Target Resuscitation Goal: P b t O 2 > 20 mmHg PbtO_2 > 20\text{ mmHg} P b t O 2 ​ > 20 mmHg .

Brain Tissue Hypoxia: P b t O 2 < 20 mmHg PbtO_2 < 20\text{ mmHg} P b t O 2 ​ < 20 mmHg .

Severe / Ischemic Hypoxia: P b t O 2 < 15 mmHg PbtO_2 < 15\text{ mmHg} P b t O 2 ​ < 15 mmHg (associated with cellular energy failure, microdialysis lactate-to-pyruvate spikes, and increased neurological mortality).

Severe hypoxia requiring urgent assessment: P b t O 2 < 10 mmHg PbtO_2 < 10\text{ mmHg} P b t O 2 ​ < 10 mmHg .

Clinical Trial Evidence & Tiered Hypoxia Resuscitation

The phase II BOOST-2 (Brain Oxygen Optimization in Severe Traumatic Brain Injury Phase II) trial demonstrated that a protocolized management protocol targeting both ICP ( < 20 mmHg <20\text{ mmHg} < 20 mmHg ) and P b t O 2 PbtO_2 P b t O 2 ​ ( > 20 mmHg >20\text{ mmHg} > 20 mmHg ) significantly reduced the cumulative duration and severity of cerebral tissue hypoxia compared to ICP-only guided therapy, with an exploratory outcome signal that did not establish definitive functional benefit. The phase III BOOST-3 trial was designed to definitively evaluate 6-month functional neurological recovery.

Management of compromised brain tissue oxygenation ( P b t O 2 < 20 mmHg PbtO_2 < 20\text{ mmHg} P b t O 2 ​ < 20 mmHg ) follows a tiered, step-wise protocol:

Tier 1 (Basic Hemodynamic & Ventilatory Optimization):

Ensure ICP < 22 mmHg < 22\text{ mmHg} < 22 mmHg (CSF drainage, sedation).

Optimize CPP to 60 – 70 mmHg 60\text{--}70\text{ mmHg} 60 – 70 mmHg with isotonic crystalloids and vasopressors (norepinephrine).

Perform an F i O 2 FiO_2 F i O 2 ​ challenge: transiently increase F i O 2 FiO_2 F i O 2 ​ to target P a O 2 ≥ 150 mmHg PaO_2 \ge 150\text{ mmHg} P a O 2 ​ ≥ 150 mmHg . A poor response may reflect local perfusion, tissue injury, position, or technical function and does not prove one cause.

Ensure normocapnia ( P a C O 2 35 – 40 mmHg PaCO_2\ 35\text{--}40\text{ mmHg} P a C O 2 ​ 35 – 40 mmHg ) to prevent hypocapnic cerebral vasoconstriction.

Tier 2 (Oxygen Delivery & Rheology Augmentation):

Augment CPP to 70 – 80 mmHg 70\text{--}80\text{ mmHg} 70 – 80 mmHg (if pressure autoregulation is intact).

Optimize oxygen-carrying capacity: transfuse packed red blood cells (PRBCs) to maintain hemoglobin ≥ 7 – 9 g/dL \ge 7\text{--}9\text{ g/dL} ≥ 7 – 9 g/dL .

Optimize cardiac index with inotropic support (dobutamine or milrinone) if hypodynamic.

Aggressively control hyperthermia (targeted temperature management to normothermia 36.0 – 37.0 ∘ C 36.0\text{--}37.0^\circ\text{C} 36.0 – 37. 0 ∘ C ).

Rule out subclinical seizures on continuous EEG.

Tier 3 (Advanced Interventions):

Neuromuscular blockade to minimize shivering and systemic oxygen consumption.

Pharmacologic metabolic suppression (propofol or pentobarbital titration to burst suppression).

Decompressive craniectomy for refractory ICP elevation.

Cerebral Microdialysis (CMD)

Cerebral microdialysis samples the biochemistry of the extracellular interstitial space, providing continuous monitoring of cellular metabolic health, substrate availability, and membrane degradation.

Principle of Operation

A fine concentric catheter with a semipermeable hollow fiber membrane (molecular weight cut-off typically 20 kDa 20\text{ kDa} 20 kDa or 100 kDa 100\text{ kDa} 100 kDa ) is inserted into brain parenchyma. An isotonic fluid (CNS perfusion fluid) is continuously pumped through the inner tube at ultra-low flow rates ( 0.3 μ L/min 0.3\text{ }\mu\text{L/min} 0.3 μ L/min ). Interstitial molecules diffuse across the semipermeable membrane down their concentration gradients into the perfusate, which is collected in microvials and analyzed hourly at the bedside.

Key Biochemical Markers & Metabolic Patterns

Biomarker Normal Brain Range Pathological Cutoff Pathophysiological Significance

Lactate 1.0 – 2.0 mmol/L 1.0\text{--}2.0\text{ mmol/L} 1.0 – 2.0 mmol/L > 3.5 – 4.0 mmol/L >3.5\text{--}4.0\text{ mmol/L} > 3.5 – 4.0 mmol/L Elevated in anaerobic glycolysis, hypermetabolism, and tissue hypoxia

Pyruvate Reference values vary with technique and tissue < 70 μ mol/L <70\text{ }\mu\text{mol/L} < 70 μ mol/L Product of glycolysis; depleted in substrate starvation and true ischemia

Lactate-to-Pyruvate Ratio ( L P R LPR L PR ) 15 – 25 15\text{--}25 15 – 25 > 40 >40 > 40 a useful local marker of redox disturbance and cytoplasmic redox failure (elevated NADH / NAD + \text{NADH}/\text{NAD}^+ NADH / NAD + )

Glucose 1.0 – 2.0 mmol/L 1.0\text{--}2.0\text{ mmol/L} 1.0 – 2.0 mmol/L < 0.8 mmol/L <0.8\text{ mmol/L} < 0.8 mmol/L Interstitial substrate delivery; severe glucopenia reflects severe ischemia or extreme hypermetabolism

Glycerol 20 – 50 μ mol/L 20\text{--}50\text{ }\mu\text{mol/L} 20 – 50 μ mol/L > 50 – 100 μ mol/L >50\text{--}100\text{ }\mu\text{mol/L} > 50 – 100 μ mol/L Marker of phospholipid cell membrane breakdown and ongoing cellular structural lysis

Glutamate 1 – 5 μ mol/L 1\text{--}5\text{ }\mu\text{mol/L} 1 – 5 μ mol/L > 10 μ mol/L >10\text{ }\mu\text{mol/L} > 10 μ mol/L Excitatory neurotransmitter; massive release indicates spreading depolarization and excitotoxicity

Important

Differentiating Ischemic vs. Non-Ischemic Metabolic Crisis:

Ischemic Bioenergetic Failure: Characterized by L P R > 40 LPR > 40 L PR > 40 accompanied by low pyruvate ( < 70 μ mol/L <70\text{ }\mu\text{mol/L} < 70 μ mol/L ) , low glucose ( < 0.8 mmol/L <0.8\text{ mmol/L} < 0.8 mmol/L ) , and severely depressed P b t O 2 PbtO_2 P b t O 2 ​ ( < 15 mmHg <15\text{ mmHg} < 15 mmHg ) . This pattern supports concern for delivery failure; verify local and systemic contributors and choose treatment from the integrated assessment.

Non-Ischemic Mitochondrial Dysfunction (Mitochondrial Distress): Characterized by L P R > 40 LPR > 40 L PR > 40 accompanied by normal or elevated pyruvate (preserved or higher pyruvate) , normal or high glucose , and adequate P b t O 2 PbtO_2 P b t O 2 ​ ( > 20 – 25 mmHg >20\text{--}25\text{ mmHg} > 20 – 25 mmHg ) . Here, oxygen and glucose delivery are intact, but damaged mitochondria are incapable of aerobic oxidative phosphorylation (due to free radical injury, calcium overload, or cytochrome oxidase dysfunction). Do not assume that automatic CPP or oxygen escalation will correct this pattern; assess cause, signal validity, and treatment response.

Transcranial Doppler (TCD) Ultrasonography

Transcranial Doppler provides non-invasive, bedside, real-time assessment of cerebral blood flow velocity (CBFV) and microvascular resistance.

Acoustic Windows & Insonation Anatomy

Transtemporal Window: Positioned superior to the zygomatic arch and anterior to the tragus:

Middle Cerebral Artery (MCA): Depth 30 – 60 mm 30\text{--}60\text{ mm} 30 – 60 mm ; blood flow directed toward the probe (positive spectral shift); normal Mean Flow Velocity (MFV) is 55 – 70 cm/s 55\text{--}70\text{ cm/s} 55 – 70 cm/s .

Anterior Cerebral Artery (ACA, A1 segment): Depth 60 – 75 mm 60\text{--}75\text{ mm} 60 – 75 mm ; blood flow directed away from the probe (negative spectral shift).

Posterior Cerebral Artery (PCA): Depth 60 – 75 mm 60\text{--}75\text{ mm} 60 – 75 mm ; P1 segment flows toward the probe, P2 segment flows away.

Terminal Internal Carotid Artery (TICA): Depth 55 – 65 mm 55\text{--}65\text{ mm} 55 – 65 mm ; bidirectional flow.

Transorbital Window: Probe placed gently over the closed eyelid using reduced acoustic power ( < 10 % – 15 % <10\%\text{--}15\% < 10% – 15% ) to avoid retinal injury:

Ophthalmic Artery: Depth 40 – 50 mm 40\text{--}50\text{ mm} 40 – 50 mm ; high-resistance flow toward the probe.

Carotid Siphon: Depth 60 – 70 mm 60\text{--}70\text{ mm} 60 – 70 mm ; bidirectional, genu, parasellar, or supraclinoid segments.

Transforaminal / Suboccipital Window: Probe placed at the base of the skull through the foramen magnum with the neck flexed:

Vertebral Arteries: Depth 55 – 75 mm 55\text{--}75\text{ mm} 55 – 75 mm ; flow directed away from the probe.

Basilar Artery: Depth 75 – 110 mm 75\text{--}110\text{ mm} 75 – 110 mm ; flow directed away from the probe; normal MFV 30 – 45 cm/s 30\text{--}45\text{ cm/s} 30 – 45 cm/s .

Surveillance for Vasospasm in Aneurysmal SAH: The Lindegaard Ratio

Following aneurysmal SAH, delayed arterial vasospasm occurs between post-bleed days 4 and 14. Accelerated blood flow velocities through narrowed arterial lumens permit non-invasive surveillance. For the Middle Cerebral Artery:

• Typical MCA MFV: 55 – 70 cm/s 55\text{--}70\text{ cm/s} 55 – 70 cm/s
• Mild Vasospasm: MFV 120 – 159 cm/s 120\text{--}159\text{ cm/s} 120 – 159 cm/s
• Moderate Vasospasm: MFV 160 – 199 cm/s 160\text{--}199\text{ cm/s} 160 – 199 cm/s
• Severe Vasospasm: MFV ≥ 200 cm/s \ge 200\text{ cm/s} ≥ 200 cm/s

However, elevated MCA velocities can also be caused by systemic hyperdynamic flow (e.g., from hypervolemia, hypertension, or inotropic therapy). To differentiate true luminal vasospasm from hyperemic flow, the Lindegaard Ratio (LR) is calculated by comparing intracranial MCA velocity to extracranial internal carotid artery velocity measured in the submandibular window: LR = MFV MCA MFV extracranial ICA \text{LR} = \frac{\text{MFV}_{\text{MCA}}}{\text{MFV}_{\text{extracranial ICA}}} LR = MFV extracranial ICA ​ MFV MCA ​ ​

LR < 3.0 \text{LR} < 3.0 LR < 3.0 : Indicates Hyperemia / Hyperdynamic flow (increased cardiac output without significant arterial narrowing).

LR 3.0 to 6.0 \text{LR } 3.0\text{ to }6.0 LR 3.0 to 6.0 : Indicates Mild to Moderate Vasospasm .

LR above 6: With high MCA velocity, supports severe vasospasm; interpret with clinical and other imaging findings.

For basilar artery vasospasm, the basilar-to-extracranial-vertebral velocity ratio (Soustiel/Sviri approach) compares basilar velocity to extracranial vertebral velocity ( > 2.5 indicates basilar vasospasm >2.5\text{ indicates basilar vasospasm} > 2.5 indicates basilar vasospasm ), or basilar MFV > 85 – 95 cm/s >85\text{--}95\text{ cm/s} > 85 – 95 cm/s .

Pulsatility Index & Cerebral Circulatory Arrest

The Gosling Pulsatility Index (PI) reflects distal cerebrovascular resistance and downstream intracranial pressure: PI = Peak Systolic Velocity (PSV) − End Diastolic Velocity (EDV) Mean Flow Velocity (MFV) \text{PI} = \frac{\text{Peak Systolic Velocity (PSV)} - \text{End Diastolic Velocity (EDV)}}{\text{Mean Flow Velocity (MFV)}} PI = Mean Flow Velocity (MFV) Peak Systolic Velocity (PSV) − End Diastolic Velocity (EDV) ​

Absent Doppler signal: This can be technical or reflect an inadequate acoustic window. It must not be used alone to diagnose circulatory arrest. An accepted adult BD/DNC TCD study requires the appropriate flow patterns, technical adequacy, and full prerequisite and clinical framework.

Evidence limit: OXY-TC (2023) did not demonstrate improved six-month neurologic outcome from adding PbtO2-guided management to ICP monitoring. BOOST-2 reduced hypoxia burden but was not definitive outcome proof. BOOST-3 is a distinct study protocol; do not invent a completed positive result. A PbtO2 probe samples local tissue, and an oxygen challenge can be affected by probe position or function as well as perfusion. Integrate these signals with the examination, imaging, gases, hemoglobin, circulation, and ICP.

Source update: 2025 Delphi panel, published 2026 emphasizes LPR with concurrent substrate levels, technique, and integrated physiology. Thresholds such as LPR above 25 or 40, glucose below approximately 1.0 mmol/L, and pyruvate below 70 micromol/L guide assessment rather than defining universal irreversible injury.